About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

IIT-Roorkee Researchers Discover Molecule That Could Fight Chikungunya

by Sushma Rao on May 5, 2018 at 9:58 AM
Font : A-A+

IIT-Roorkee Researchers Discover Molecule That Could Fight Chikungunya

A molecule that exhibits antiviral activity against the chikungunya virus, raising hopes of finding a new way to combat the mosquito-borne viral disease, reveal scientists at the Indian Institute of Technology-Roorkee.

Chikungunya causes severe fever and joint pain. At present, there are no drugs or vaccine available in the market to treat it.

Advertisement


The antiviral activity achieved around 99 per cent reduction in the virus, said the study published in the journal Biochimie.

The team used structure-based studies of chikungunya virus specific nsP2 protease to identify two molecules -- Pep-I and Pep-II -- that exhibited protease inhibitory as well as antiviral activity.
Advertisement

Out of the two molecules, the researchers found PeP-I to be more effective as an antiviral molecule.

"The nsP2 protease is a strict viral enzyme, meaning it is absent in humans, and thus, is an excellent antiviral drug target for chikungunya virus," said lead researcher Shailly Tomar, Professor at IIT-Roorkee's Department of Biotechnology.

"Our research group has targeted nsP2 using biochemical and structure-based approach. We identified a molecule that not only possesses anti-nsP2 activity but also effectively kills the chikungunya virus in the cell based assays," Tomar said in a statement.

One of the two molecules -- Pep-I -- has higher antiviral activity against chikungunya virus. The PeP-I molecule inhibits the enzymatic activity of nsP2 viral protein and in cell based assay proved to be an effective antiviral molecule.

"Derivatives of PeP-I and PeP-I like molecules are being developed that will be tested for their antiviral potential in animal model," Tomar said.

According to the researchers, any molecule that inhibits nsP2 protease should possess antiviral activity.

To test the hypothesis they carried out antiviral studies using cell lines.

The Pep-II molecule showed reduced antiviral activity of only 50 per cent even at a higher concentration, the study said.

The antiviral activity was tested by adding the molecules directly into the virus culture. The two molecules also reduced the viral RNA thus confirming the antiviral activity

"Out of the two molecules, PeP-I is more effective as an antiviral molecule as no virus was detected in cultured cells at concentration as low as 10 mM (microMolar)," study co-author Rajat Mudgal from IIT-Roorkee said.



Source: IANS
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First-Ever Successful Pig-To-Human Kidney Transplantation
World Osteoporosis Day 2021 -
Spirituality and Mental Health
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Dengue and Homeopathy Chikungunya and Homeopathy Chikungunya 

Recommended Reading
Chikungunya
Chikungunya is a viral disease spread by mosquito bites; it causes fever, severe joint pain and ......
New Insights on Chikungunya Virus and Chronic Joint Pain
One fourth of the patients infected with chikungunya have chronic joint pain. However, the virus ......
Delhi Has Reported 3,829 and 502 Cases Of Dengue and Chikungunya So Far
Delhi has so far recorded 3,829 cases of dengue and 502 cases of chikungunya, according to civic ......
Smartphone-pocket Device To Detect Zika, Dengue, Chikungunya
The tool is a smartphone-integrated system that can diagnose more than one infection with a droplet ...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use